title: Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
abstract: In this study, we have compared the protection afforded by a recombinant turkey herpesvirus vaccine expressing the H5 gene from a clade 2.2 H5N1 strain (rHVT-H5) and a Mexican-origin H5N2 inactivated vaccine, alone or in combination, against two antigenically divergent H5N1 Egyptian strains isolated in 2007 and 2008. Our results confirm the existence of a major antigenic drift among the Egyptian H5N1 strains such that, although protection against the "classical" 2007 HPAI H5N1 Egyptian strain could be obtained with both types of vaccines, only vaccination with the rHVT-H5 vaccine protected against challenge with the "variant" 2008 HPAI H5N1 Egyptian strain.
authors.affiliation: Avian Virology and Immunology Unit, Veterinary and Agrochemical Research Centre (VAR), Groeselenberg 99, 1180 Ukkel, Brussels, Belgium. farau@var.fgov.be
authors.forename: F
authors.initials: F
authors.lastname: Rauw
authors.forename: V
authors.initials: V
authors.lastname: Palya
authors.forename: S
authors.initials: S
authors.lastname: Van Borm
authors.forename: S
authors.initials: S
authors.lastname: Welby
authors.forename: T
authors.initials: T
authors.lastname: Tatar-Kis
authors.forename: Y
authors.initials: Y
authors.lastname: Gardin
authors.forename: K Moore
authors.initials: KM
authors.lastname: Dorsey
authors.forename: M M
authors.initials: MM
authors.lastname: Aly
authors.forename: M K
authors.initials: MK
authors.lastname: Hassan
authors.forename: M A
authors.initials: MA
authors.lastname: Soliman
authors.forename: B
authors.initials: B
authors.lastname: Lambrecht
authors.forename: T
authors.initials: T
authors.lastname: van den Berg
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002645:Chickens; D004337:Drug Carriers / Q000008:administration & dosage; D005822:Genetic Vectors / Q000235:genetics; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics / Q000276:immunology*; D026002:Herpesvirus 1, Meleagrid / Q000235:genetics; D007117:Immunization, Secondary / Q000379:methods; D053124:Influenza A Virus, H5N1 Subtype / Q000235:genetics / Q000276:immunology*; D053125:Influenza A Virus, H5N2 Subtype / Q000235:genetics / Q000276:immunology; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology*; D005585:Influenza in Birds / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods; D015164:Vaccines, Inactivated / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D004337:Drug Carriers; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; C109963:hemagglutinin, avian influenza A virus